FINEARTS-HF – Medxy AI

Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF

By MedXY 01/16/2026

A prespecified analysis of the FINEARTS-HF trial demonstrates that the mineralocorticoid receptor antagonist finerenone consistently reduces cardiovascular death and heart failure events in patients with HFmrEF/HFpEF, regardless of baseline KDIGO kidney risk category, while maintaining a manageable safety profile.

Cardiology Internal Medicine news

Finerenone Provides Robust Protection Against Heart Failure Events Regardless of Baseline NYHA Functional Class

By MedXY 01/16/2026

A prespecified analysis of the FINEARTS-HF trial confirms that finerenone reduces cardiovascular death and heart failure events in patients with HFmrEF and HFpEF across all symptomatic stages, offering the greatest absolute benefit to those with more severe functional limitations.

Cardiology Nephrology news

Comprehensive Summary of the FINEARTS-HF Trial Results on Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

By MedXY 12/03/2025

The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, and recent heart failure worsening.

Cardiology Specialties

Finerenone Efficacy and Safety Across Frailty Levels in Heart Failure: Insights from the FINEARTS-HF Trial

By MedXY 09/13/2025

This analysis of the FINEARTS-HF trial reveals that finerenone reduces cardiovascular death and heart failure worsening regardless of frailty status, without increasing adverse events, supporting its use in frail patients with HFmrEF or HFpEF.